Guardian Bio
Private Company
Reinventing dendritic cell therapy for solid tumors
Biotechnology
2-10 employees
Founded 2022
About Guardian Bio
Guardian Bio is a biotechnology company reinventing dendritic cell therapy for solid tumor cancers. Its platform develops personalized treatments by transforming patient-derived stem cells into both off-the-shelf and autologous therapies. These treatments are designed to activate a robust anti-tumor immune response in patients and are targeted towards healthcare providers and cancer centers.
Company Classification
Customer Types
B2B
Business Models
Products
Product & Service Types
Personalized Cell TherapiesCancer ImmunotherapyDendritic Cell-Based Treatments
Funding
Total Funding
$500.0K
No. of Funding Rounds
1
Sign up to Ethos to access the full customer list, plus detailed competitor and product analysis.
Sign up to Ethos